

Index

Note: Page numbers followed by f indicate a figure on the corresponding page. Page numbers followed by t indicate a table on the corresponding page.

- abortive apoptosis, 35
- acidified Tyrode’s solution, 151
- adenosine monophosphate (AMP), 83
- adenosine salvage pathway, 46
- adenosine triphosphate (ATP)
 - cellular energy context in IVF, 82–5
 - developmental competence and, 95
 - in embryo development, 82
 - intensity of autofluorescence and, 94
 - metabolic loading and, 45–6
 - mitochondrial DNA and, 85, 87–8
 - oxygen consumption rates, 89–91
- adjuvant therapies for implantation, 26, 27–8t
- adult-onset diseases and embryo selection, 173–5, 174f
- advanced female reproductive age (ARA), 140, 143, 159
- age factors in patients, 62
- allele dropout (ADO), 136–7
- altered blastocyst gene expression, 175
- amino acids, 16–17, 67, 125, 127, 130
- amniocentesis, 146, 158
- anaphase I (AI), 11
- aneuploidy, *see* chromosomal anomalies in embryos
- annexin V-conjugated microbeads, 172
- array-comparative genomic hybridization (a-CGH), 139–40, 143, 161
- artificial intelligence (AI), 6, 51, 123, 130, 169–71, 171f, 171t
- aspartate assay, 128
- assessment of DNA fragmentation, 36–8, 37t
- assisted reproduction technology (ART), *see also* laboratory systems in ART; oocyte processing in ART; sperm manipulation and assessment for ART
 - abortive apoptosis, 35
 - evolution of, 168–9t, 169
 - expanded use of, 49
 - live birth success after, 15
 - as routine treatment, 10, 14
 - sperm manipulation and assessment for, 38–40, 38–9t
 - in vitro* maturation in, 51
- autofluorescence, 51, 92–6
- Barker hypothesis, 174
- Beckwith–Wiedemann syndrome, 75
- bioenergetics in developmental competence
 - cellular energy context in IVF, 82–5
 - historical perspective, 82
 - introduction to, 81–2
 - key points, 90–6
 - mitochondria and, 85–6
 - mtDNA copy number and, 86–9
 - noninvasive autofluorescence, 92–6
 - oxygen consumption rates, 89–91
 - Raman spectroscopic analysis, 88f, 91–6
 - scanning electrochemical microscopic system, 90–1
 - semi-quantitative estimations of, 88f, 92–5
 - summary of, 95–6
- biopsy techniques in preimplantation genetic testing
 - acidified Tyrode’s solution, 151
 - blastomere biopsy, 152
 - introduction to, 149
 - IVF clinic implementation of, 149–51
 - key points, 155
 - laser-assisted opening, 151
 - mechanical ZP opening, 151
 - overview, 159–60, 159–60t
 - polar body (PB) biopsy, 149, 151–2
 - trophectoderm (TE) biopsy, 152–5
 - zona pellucida (ZP) opening procedure, 151
- birefringence, 172
- birth rate declines, 4–5
- “black box” concept, 170
- blastocentesis technique, 160–1, 161f
- blastocoele, 23, 160–1
- blastocyst complementation, 168
- blastocyst fluid for cfDNA screening
 - blastocentesis technique, 160–1, 161f
 - evidence for, 161
 - investigations of concordance between, 161–3, 162–3f
 - overview of, 160–3
 - principle of, 160
- blastocysts/blastocyst stage
 - cryosurvival rates, 5
 - development rates, 62
 - events of implantation, 23–4, 24–8f
 - formation of, 11, 14, 17
 - fully hatched blastocyst, 154–5
 - grade of expansion, 107
 - inner cell mass and, 108
 - morula-to-blastocyst transition, 90
 - poor-quality blastocyst, 154–5
 - static evaluations for morphological assessment, 107–9, 108f
 - trophectoderm (TE) cells, 108–9
 - vitrification procedure, 4–6, 150
- blastomere biopsy, 149, 151–2, 155, 158
- blastulation, 15, 106
- blood vessel changes, 23
- body mass index (BMI), 15, 24, 46–51
- Brown, Louise, 1
- calcium pulsations, 11
- capacitation, defined, 65
- cell-free DNA (cfDNA) screening for PGT-A, *see also* blastocyst fluid for cfDNA screening
 - blastocyst fluid as source, 160–3, 163f
 - development of PGT-A, 158–9
 - evidence in blastocyst fluid, 161
 - indications for PGT-A, 159
 - introduction to, 158
 - key points, 166
 - miRNAs and exomes, 165
 - spent culture medium, 165–7
 - summary of, 165
 - TE biopsy, 160
- cell number and stage appropriateness, 103, 104f
- chemical-energy requiring processes, 84

- chemokines, 23–4
chorionic villus sampling, 158
chromatin modelling, 13
chromosomal anomalies in embryos,
 1–2, 43, 119–20, 135–6, 140–6,
 144f
citric acid cycle, 84
cleavage stage
 aneuploidy in embryos, 121
 assessment timing, 103
 cell number and stage
 appropriateness, 103, 104f
 defined, 103
 fragmentation, 104–6, 105f
 introduction to, 3, 10–11
 static evaluations for morphological
 assessment, 103–6
 symmetry during, 104f, 104
 timing of divisions, 14, 15f
 uneven cleavage and
 multinucleation, 106
cMOS proto-oncogene, 50
CO₂ levels in incubator environment,
 63
comet assay, 36–7
comparative genomic hybridization
 (CGH), 138–9
competency in embryogenesis, 44–5,
 45t
comprehensive chromosome testing
 (CCT) techniques, 149–50
Confocal Raman Spectroscopy (CRS),
 7f, 91–6, 130, 173
contact materials in ART culture
 environment, 64
Cornell University Medical College,
 158
CRISPR/CAS9 genome editing tool, 168
cryopreservation, 5, 43, 62, 65, 150
cryosurvival rates, 4–6
culture environment/system
 in ART laboratory, 62–4
 condition challenges, 5–6
 embryo processing in ART, 68
 impact on metabolism, 125
 laboratory's role in embryogenesis
 and, 53
 protection against changes in, 64
 of *in vitro* fertilization, 10, 15
cumulative live birth rate (CLBR), 151
cumulus cell metabolism, 45–6, 47f, 48
cumulus-oocyte complexes (COCs), 63,
 66–7
cytoplasmic bioenergetics, 87
cytoplasmic fragmentation, 104–6,
 105f, 105
cytoplasmic halo, 101–3, 102f
cytoplasmic maturation promoting
 factor (MPF), 11
cytoplasmic organization, 84, 89
cytoskeleton, 12, 22–9, 48, 50–1, 73
cytostatic factor (CSF), 11
D-loop (displacement loop), 85
day 3 ZP opening-based TE biopsy, 149
day 5 useable blastocyst rate (D5BUR),
 56–8, 60
day 5–7 sequential ZP opening and TE
 fragment retrieval, 149
decapacitation factor(s), 65
decidualization, 22–4
dendritic cells, 23
density-gradient centrifugation, 39–40
developmental competence, *see*
 bioenergetics in developmental
 competence
diploidy establishment, 10–12
DNA (deoxyribonucleic acid), *see also*
 cell-free DNA (cfDNA) screening
 for PGT-A; mitochondrial DNA
 contamination, 150–1
 demethylation of, 13, 15, 32
 embryonic DNA, 160
 histone-based nucleosomes,
 33–4
 integrity of, 34–6, 35f
 methylation of, 15, 33–4
 mtDNA mutations, 82
 non-nucleosomal, 46
 nuclear matrix attachments, 32
 packaging and delivery in sperm,
 32–3, 33f
 protamines, 32–5
 repair processes, 103
 sequencing methods, 81
DNA (deoxyribonucleic acid)
 fragmentation
 assessment techniques, 36–8, 37t
 comet assay, 36–7
 in situ nick translation, 38
 sperm chromatin dispersion assay,
 38
 sperm chromatin structure assay, 31,
 37–8
 sperm DNA integrity and, 34–6*see*
 also (preimplantation genetic
 testing)
 summary of, 40–1
 terminal deoxynucleotidyl
 transferase dUTP nick end
 labeling, 36
DNA fragmentation index (DFI), 172
double refraction, 172
dual photon microscope, 92
dynamic evaluations for morphological
 assessment, *see* time-lapse
 imaging
dystroglycan, 22
Ebner, Thomas, 113
Edwards, Robert G. (Bob), 1, 100
electron microscopy analysis, 72
embryo metabolism
 amino acids and, 16–17
 in development, 15–17
 energy substrate, 16–17
 hyperglycaemia and metabolic stress,
 16–17
 post genomic activation, 16–17
 pre genomic activation, 16
 reactive oxygen species, 16
embryo nutrient utilization analysis
 aspartate assay, 128
 assays and platforms, 123–7
 assessment of, 125–7, 126–7f
 cultural conditions and, 125
 embryo viability and, 123–5, 124f
 enzyme-linked assays, 123–7
 glucose assay, 128
 glutamine assay, 128
 introduction to, 123, 124f
 key points, 132–3
 lactate assay, 128
 metabolomic platforms, 130
 microfluidics technologies, 129–30,
 131f
 nanodrop technology, 129
 novel microscopies, 130
 plate reader technology, 129
 platforms for, 123–8
 pyruvate assay, 128
 summary of, 130–2, 132f
 ultramicrofluorescence, 128–30
embryo processing in ART
 culture medium system, 68
 fertilization assessment, 68
 overview, 68
embryo selection
 adult-onset diseases and, 173–5, 174f
 artificial intelligence for, 169–71,
 171t, 171f
 Confocal Raman Spectroscopy, 88f,
 91–6, 130, 173
 cumulative results, 5
 debate over safety concerns, 175
 early IVF timeline, 1, 2f
 evolution of ART, 168–9t, 169
 fluorescence lifetime imaging
 microscopy, 92, 130, 173
 future challenges, 5–6, 6f
 future of, 177
 Gradient Light Interference
 Microscopy, 173
 improvements in transferred
 embryos, 4–5
 interferometric phase microscopy,
 173
 introduction to, 168

Index

- embryo selection (cont.)
 key points, 175
 label-free microscopy, 172–3
 novel technologies for, 169–70*t*, 169–75
 polarization microscopy, 172–3
 process of, 1–4, 2–5*f*, 3*f*
 summary of, 6, 175
 time-lapse algorithms for, 119–21
 embryogenesis/embryo development,
see also gamete's role in
 embryogenesis; laboratory's role in
 embryogenesis; sperm's role in
 embryogenesis
 activating process of,
 95–6
 blastocyst formation, 11
 blastulation, 15
 cleavage stages, 3, 10–11
 developmental programming, 11–14
 embryogenesis and, 11–14, 13*f*
 embryonic genome activation, 12–13
 fertilization and establishment of
 diploidy, 11–12
 fertilization events, 10
 gaps in knowledge, 10
 implantation and, 11
 initiation of, 12
 introduction to, 1–2, 10
 key points, 17–18
 kinetics of, 14–15
 lineage commitment, 13–14
 maternal determinants of, 44–7
 maternal programme for, 11–12
 metabolic needs, 15–17
 morula formation, 14
 oocyte maturation, 11
 oogenesis and, 43, 47–51
 preimplantation embryo
 development, 10–11, 12*f*
 preimplantation embryogenesis,
 81–2, 87, 90–6
 summary of, 17
 syngamy and, 12
 timing of cleavage divisions, 14, 15*f*
 embryology key performance
 indicators, 53, 55–60
 embryonic DNA, 160
 embryonic genome activation, 12–13
 embryonic stem cells (ESCs), 168
 endometrial cyclicity, 20–3, 21–8*f*
 endometrial development, 25
 endometrial receptivity, 4, 20, 25–8
 Endometrial Receptivity Array (ERA),
 26–30
 endometrial scratch, 26
 energy substrate, 16–17
 epigenetics, 31, 33–4, 41
 epithelial cell polarity, 22
 ERPeak, 26
 extracellular vesicles (EV), 24
 extrinsic mediators of embryogenesis,
 48–9
 failure modes and effect analysis
 (FMEA), 150
 Fallopian tubes, 20, 21–8*f*
 fecundity rates, 3–4
 fertilization process, 10–12, 65, 68
 first polar body, 73, 73*f*
 flavin adenine dinucleotide (FAD), 92,
 95–6, 173
 flicking method, 153
 fluorescence lifetime imaging
 microscopy (FLIM), 92, 130, 173
 fluorescent emission wavelength, 87
 fluorescent in situ hybridization
 (FISH), 137–8, 141, 158–9
 flushing embryos from uterus, 168
 follicle stimulating hormone (FSH), 25
 follicular fluid, 48, 66–7
 follicular growth, 1–4, 2–5*f*, 3*f*, 46
 folliculogenesis, 72
 fragmentation, *see also* DNA
 (deoxyribonucleic acid)
 fragmentation
 cleavage stage, 104–6, 105*f*
 cytoplasmic fragmentation, 104–6,
 105*f*, 105
 sperm DNA fragmentation, 31, 36–8,
 37*t*
 free radical generation, 46
 free radical neutralizing, 46
 freeze–thaw cycles, 25–6, 26*t*
 freeze–thaw procedures, 5
 FSH stimulation, 1
 fully hatched blastocyst, 154–5
 gamete's role in embryogenesis
 current clinical standards, 44*f*, 44
 future research directions, 50–1
 intrinsic and extrinsic mediators of,
 48–9
 introduction to, 43
 key points, 51
 maternal determinants of,
 44–7
 metabolic loading during ovulation,
 45–6, 47*f*
 molecular determinants of, 47–8, 49*f*
 monitoring developmental
 competence, 44–5, 45*t*
 oocyte competence in, 49–50
 patient health status, 46–7
 selection through cell sorting, 171–2
 subcortical membrane complex, 50
 gametogenesis, 3*f*, 6, 62, 168
 gene mutations, 135
 genetic mosaicism, 81
 genome-wide association study
 (GWAS), 173–4
 germinal vesicle (GV), 11, 70, 71*f*
 glandular epithelium, 22
 glass wool filtration, 40
 glucose assay, 128
 glucose uptake and embryo viability
 relationship, 123–5, 124*f*
 glutamine assay, 128
 glycocalyx thinning, 22
 glycosylation, 85
 “goldilocks” hypothesis, 172–4
 Gradient Light Interference
 Microscopy (GLIM), 173
 granular cytoplasm, 75–6
 guanosine triphosphate (GTP), 82–5, 95
 Hamamatsu OCRA R2 camera, 93
 health factors in patients, 62
 heparin-like EGF-like growth factor
 (HB-EGF), 22
 high performance liquid
 chromatography (HPLC), 127
 histone-based nucleosomes, 33–4
 hormonal levels with implantation, 25
 human chorionic gonadotropin (hCG),
 25
 human menopausal gonadotropins
 (hMG), 1
 hyperglycemia, 16–17
 hyperspectral auto-fluorescence
 microscopy, 130
 iatrogenic zona hardening, 90
 implantation
 adjuvant therapies for, 26, 27–8*t*
 blood vessel changes, 23
 elevated BMI and, 24
 embryo developmental
 programming, 11
 endometrial cyclicity, 20–3, 21–8*f*
 endometrial development effects, 25
 endometrial receptivity, 26–8
 endometrial scratch, 26
 epithelial cell polarity, 22
 events of implantation, 23–4, 24–8*f*
 freeze–thaw cycles, 25–6, 26*t*
 glandular epithelium, 22
 hormonal levels with, 25
 infertility clinic impact, 25–6
 introduction to, 20, 21–8*f*
 leukocyte infiltration, 23
 luminal epithelial cells, 22
 ovarian stimulation effects, 25–6
 ovulation induction effects, 25
 rates of, 4–5
 stromal cell decidualization, 22–3
 summary of, 26–8
 uterine tract microenvironment, 24
 imprinted genes, 15, 33–4, 175
in situ nick translation, 38
in vitro fertilization (IVF)
 assessing developmental
 competence, 81

- cellular energy context in, 82–5
- clinic implementation of biopsy techniques, 149–51
- culture environment, 10, 15
- embryo growth, 53
- improving efficacy, 135
- insemination process, 67
- male infertility, 31–2
- noninvasive selection of oocytes, 70
- oocyte donor use in, 46
- oocytes fitness, 43
- rates of, 56
- sperm preparation process for, 65
- in vitro* fertilization (IVF) laboratory, *see* laboratory systems in ART; laboratory's role in embryogenesis
- in vitro* maturation (IVM), 51
- in vivo* environment, 53
- incubation system in ART culture environment, 64
- inducible pluripotent stem cells (iPSCs), 168
- inner cell mass (ICM), 11, 13–14, 23, 107–8, 135, 160
- Institutional Review Boards (IRBs), 175
- interferometric phase microscopy (IPM), 173
- International Society of Preimplantation Genetic Diagnosis (PGDIS), 144
- intracellular morphology of oocytes
 - granular cytoplasm, 75–6
 - in noninvasive selection of, 73–6
 - refractile bodies, 74, 74f
 - smooth endoplasmic reticulum, 74–5, 75–6f
 - vacuoles, 73–4
- intracytoplasmic sperm injection (ICSI)
 - abortive apoptosis in, 35
 - blastocentesis technique, 160–1, 161f
 - effects of ART on offspring health, 15
 - fertilization assessment in embryo processing, 68
 - fertilization rates, 56
 - male involvement in, 31–2, 67–8
 - noninvasive selection of oocytes, 70
 - oocytes fitness, 43, 51
 - sperm deposition within a vacuole, 74
 - TE biopsy and, 150
- intrinsic mediators of embryogenesis, 48–9
- IVF–ET cycle, 26
- karyomapping, 137, 138f
- key performance indicators (KPIs) in embryogenesis, 53, 55–60, 57–8t
- label-free microscopy, 172–3
- laboratory systems in ART
 - contact materials, 64
 - culture medium protection, 64
 - culture system in, 62–4
 - embryo processing, 68
 - incubation system, 64
 - introduction to, 3, 62
 - key points, 68
 - light suppression in, 64
 - oocyte processing, 66–8
 - osmolality and, 64
 - ovarian stimulation protocols, 62
 - oxygen levels in, 63
 - pH range of cultures, 63
 - sperm processing, 65–6
 - temperature control, 63
- laboratory's role in embryogenesis
 - biological effects of environmental stressors, 54
 - culture environment, 53
 - embryo selection, 59–60
 - introduction to, 53
 - key performance indicators in, 53, 55–60, 57–8t
 - key research points, 60
 - summary of, 60
 - time-lapse incubators, 56
 - useable blastocyst rates, 56–8
- lactate assay, 128
- laser-assisted opening, 151
- Leica EVOS fluorescent microscope, 93
- leukocyte infiltration, 23
- light suppression in ART culture environment, 64
- lineage commitment, 13–14
- liquid chromatography-mass spectrometry (LC-MS), 130
- low motility sperm samples, 65–6
- low sperm concentration samples, 65
- luminal epithelial cells, 22
- magnetic-activated cell sorting (MACS), 171–2
- male factor infertility (MF), 31, 140
- mass spectrometry, 127–30
- mast cells, 23
- maternal-embryonic interactions, 20, 21–8f
- maternal mRNA, 13
- maternal program for development, 11–12
- maturation promoting factor (MPF), 11
- maturation stage of oocytes, 70–1, 71f
- mechanical-energy requiring processes, 84
- mechanical ZP opening, 151
- meiosis, 1, 11, 70–1, 71f
- meiotic maturation
 - mtDNA competence and, 86–7
 - oocyte competence and, 48
 - oocyte development and, 85
 - process of, 48
 - spindle positioning during, 76
- metabolic loading during ovulation, 45–6, 47f
- metabolic stress, 16–17
- metabolomic platforms, 130
- metaphase CGH, 139
- metaphase I (MI) stage of meiosis, 11, 70–1, 71f
- metaphase II (MII) stage of meiosis, 70–1, 71f
- microdrop volume, 163–4
- microfluidic technique for isolating sperm, 40, 41f, 129–30, 131f, 172
- microRNAs (miRNAs), 165
- migration-sedimentation technique, 39
- minimally invasive genetic testing, 151
- mitochondrial DNA (mtDNA)
 - copy number and developmental competence, 86–9
 - in developmental competence, 85–6
 - function and dysfunction in, 85–6
 - mutations, 82
 - noninvasive assessment, 86
 - stage-specific spatial reorganization, 87–9
- mitochondrial metabolism, 46, 86, 92
- mitochondrial transfer, 168
- mitosis, 2, 3f, 12, 17, 50, 103–4
- molecular cytogenetic methodologies, 138–9
- monogenic disorders, 136–7
- morphodynamic processes, 90
- morphokinetics, 50–1
- morula formation, 14, 18, 117, 125
- morula-to-blastocyst transition, 90
- mosaicism, 143–6, 162
- mouse embryo assay (MEA), 64
- mRNA fertilization, 50
- multiday scoring for morphological assessment, 109–10
- multinucleation with uneven cleavage, 106
- nanodrop technology, 129
- near-infrared (NIR) spectroscopy, 130
- next-generation sequencing (NGS), 139–40, 141f
- nicotinamide adenine dinucleotide (NAD), 92, 94–6, 173
- nicotinamide adenine dinucleotide phosphate (NADPH), 92, 94–6
- Nikon Diaphot microscope, 93
- Nikon inverted microscope, 93
- noninvasive selection of oocytes, *see also* intracellular morphology of oocytes
 - first polar body, 73, 73f
 - introduction to, 70, 71f
 - maturation stage, 70–1, 71f

Index

- noninvasive selection of oocytes, *see also* (cont.)
 morphological assessment and scoring, 76
 oocyte dysmorphisms, 80
 perivitelline space, 72, 73*f*
 shape considerations, 71, 72*f*
 size considerations, 72
 summary of, 76–80
 zona pellucida, 72
non-nucleosomal DNA, 46
noninvasive autofluorescence, 51, 92–6
nuclear magnetic resonance (NMR) imaging, 130
nuclear matrix attachments, 32

observer-based morphological assessments, 91
Olympus IX 82 widefield fluorescent microscope, 93
oocyte competence in embryogenesis, 49–50
oocyte maturation, 11, 44, 49–51, 70, 88
oocyte pick-up (OPU), 66–7
oocyte processing in ART, *see also* noninvasive selection of oocytes
 equilibration and set-up, 66
 insemination process, 67–8
 intracellular morphology, 73–6
 overview of, 66–8
 retrieval process, 66–7
oocyte's role in embryogenesis, *see* gamete's role in embryogenesis
oogenesis
 aneuploidy during, 159
 cellular bioenergetics and, 82
 complexity of, 1
 cytoplasm stored during, 72
 developmental competencies and, 44–5, 45*f*, 45*t*
 embryogenesis and, 43, 47–51
 growth phase of, 46, 47*f*
 osmolarity in ART culture environment, 64
ovarian hyperstimulation stimulation syndrome (OHSS), 25
ovarian stimulation protocols, 62, 106
ovulation, 25, 45–6, 47*f*, 66
oxidative stress and sperm, 34
OXPHOS diseases, 82
oxygen consumption rates (OCR), 16–17, 89–91
oxygen levels in ART culture environment, 63

partial-zona-dissection (PZD) microneedle, 151
patient health status, 46–7
percutaneous epididymal sperm aspiration (PESA), 66

peri-blastulation delays, 120
peri-implantation stage human embryo, 86
pericortical cytoplasm, 93
perivitelline space (PVS), 70, 72, 73*f*
permeable chemical intracellular thermometer, 87
pH range in ART culture environment, 63
phospholipase-zeta (PLCZ), 11
pinopodes, 22
plasma membrane transformation, 22
plate reader technology, 129
ploidy mosaicism, 121
pluripotent stem cell induction, 168
polar body (PB) biopsy, 149, 151–2
polarization microscopy, 172–3
polycystic ovary syndrome, 159
polymerase chain reaction (PCR), 136, 140
poor-quality blastocyst, 154–5
pre genomic activation, 16
preimplantation embryogenesis, 81–2, 87, 90–6
preimplantation genetic diagnosis (PGD), 135
preimplantation genetic testing for aneuploidy (PGT-A), *see also* biopsy techniques in preimplantation genetic testing; cell-free DNA (cfDNA) screening for PGT-A
 development of, 158–9
 indications for, 159
 introduction to, 6
 time-lapse imaging, 119–20, 135–6, 140–6, 144*f*, 149
preimplantation genetic testing for monogenic disorders (PGT-M), 136–7, 145, 149, 158
preimplantation genetic testing for structural rearrangements (PGT-SR), 135, 137–43, 149, 158
preimplantation genetic testing (PGT), *see also* biopsy techniques in preimplantation genetic testing
 allele dropout, 136–7
 introduction to, 135–6
 karyomapping, 137, 138*f*
 for monogenic disorders, 136–7
 mosaicism and, 143–6
 short tandem repeat, 136–7
 for structural rearrangements, 137–40, 140–1*f*
 summary of, 144–6
 time-lapse imaging, 130, 135
primordial follicles, 1, 46, 47*f*, 70
pronuclear membrane breakdown, 102–3
prophase II (PII), 11
proprotein convertase (PC), 22

protamines, 32–5
proteostasis, 48, 50
Purdy, Jean, 1
pyruvate assay, 128

Quiet Embryo hypothesis, 17, 132, 172–4

“Rate and Fate” Hypothesis, 125
reactive oxygen species (ROS), 16, 32, 34–5, 65
ReceptivaDx test, 26
recurrent pregnancy losses (RPL), 136
refractile bodies, 74, 74*f*
repeated implantation failure (RIF), 136
reproductive cloning, 168
respiration-based competence assessment, 89
respiratory chain complex, 83
retrograde ejaculation samples, 66
RNA
 microRNAs, 165
 mRNA fertilization, 50
 rRNA synthesis, 100
 sperm's role in embryo development, 34
 stability of, 48

scanning electrochemical microscopic (SECM) system, 90–1
Seahorse XF analyzers, 89
second meiotic metaphase (MII), 11
serum beta human chorionic gonadotropin (βhCG), 58
short tandem repeat (STR), 136–7
S.I.S.Me.R. Reproductive Medicine Unit, 159
smooth endoplasmic reticulum (SER), 74–5, 75–6*f*
Society of Assisted Reproductive Technology (SART), 4
somatic-cell nuclear transfer, 168
spent culture medium
 microRNAs in, 165
 principle behind collection, 163
 reliability of cfDNA testing in, 164–5, 164–5*t*
 as source of cell-free DNA, 165–7
 technique for collection, 163–4
sperm chromatin dispersion assay, 38
sperm chromatin structure assay (SCSA), 31, 37–8
sperm DNA fragmentation, 31, 36–8, 37*t*
sperm manipulation and assessment for ART
 comparisons of, 38–40, 38–9*t*
 cryopreserved sperm samples, 65
 density-gradient centrifugation, 39–40

- glass wool filtration, 40
- low motility sperm samples, 65–6
- low sperm concentration samples, 65
- microfluidic technique for isolating sperm, 40, 41f
- migration-sedimentation technique, 39
- other techniques, 40
- preparation methods, 65
- processing in laboratory systems, 65–6
- retrograde ejaculation samples, 66
- surgically retrieved sperm samples, 66
- swim-up method, 38–9
- unusual sperm/semen samples, 65–6
- spermatogenesis, 2, 34, 159
- sperm's role in embryogenesis
 - assessment of DNA fragmentation, 36–8, 37t
 - DNA integrity, 34–6, 35f
 - DNA packaging and delivery, 32–3, 33f
 - epigenetics and, 33–4
 - histone-based nucleosomes, 33–4
 - introduction to, 31
 - key points, 41
 - manipulation and assessment for ART, 38–40, 38–9t
 - mechanics of, 32–6
 - nuclear matrix attachments, 32
 - protamines, 32–5
 - RNA and, 34
 - summary of, 40–1
- static evaluations for morphological assessment
 - in blastocyst stage, 107–9, 108f
 - cleavage stage, 103–6
 - in compaction phase, 106–10
 - cumulative scoring, 109–10
 - cytoplasmic halo, 101–3, 102f
 - introduction to, 100, 101f
 - key points, 109–10
 - pronuclear pattern, 100–1, 102f
 - zygote stage, 100–3
- Steptoe, Patrick, 1
- STORK framework, 170–1
- stromal cell decidualization, 22–3
- structural chromosome rearrangements, 137–40, 140–1f
- subcortical membrane complex (SCMC), 50
- subplasmalemmal cytoplasm, 87, 101
- surgically retrieved sperm samples, 66
- swim-up method, 38–9
- syngamy and embryo developmental programming, 12
- T cells, 23
- telophase I (TI), 11
- temperature control in ART laboratory, 63
- terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL), 36
- testicular sperm aspiration (TESA), 66
- testicular sperm extraction (TESE), 31, 66
- tetrahedral blastomere configuration, 106–10
- therapeutic cloning, 168
- thermodynamically unfavorable processes, 84
- three electrode Clark sensor system, 89
- time-correlated single photon counting (TCSPC), 173
- time-lapse imaging (TLI)
 - algorithms for embryo selection, 119–21
 - annotation of, 116–18, 117f
 - benefits of, 113
 - chromosomal anomalies in embryos, 119–20
 - clinical benefits, 119–20
 - considerations in IVF laboratory, 114
 - data handling and analysis, 119f, 119
 - dish or slide preparation, 118
 - historical perspective and background, 113
 - incubators and, 56
 - introduction to, 14
 - key points, 119–21
 - patient information on, 118–19
 - practical tips for, 117–19
 - uses of, 114–16f, 116
- time-lapse (TL) methodology, 5–6
- timing of cleavage divisions, 14, 15f
- total useable blastocyst rate (TBUR), 56–8
- tracking key performance indicators, 58–9
- transcription factors, 13–14, 17
- transcriptional inhibitors, 12
- transferred embryos, 4–5
- translational protein modifications, 48
- translucent cytoplasm, 101
- transmission electron microscopy (TEM), 73, 87
- trichotomous mitosis, 104
- tripeptide glutathione, 46
- trophectoderm (TE) biopsy
 - blastocyst fluid in cfDNA screening, 161–3, 162–3f
 - blastocyst protocols, 152–3, 154f
 - blastocyst selection, 152, 153f
- day 3 ZP opening-based TE biopsy, 149
- day 5 useable blastocyst rate, 56–8, 60
- day 5–7 sequential ZP opening and TE fragment retrieval, 149
- flicking method, 153
- focus issue, 153–4
- IVF clinic, 149–51
- overview, 159–60
- peculiar cases and troubleshooting, 154–5
- quality of sample, 154, 155f
- techniques of, 152–5
- zona pellucida and, 152–3, 154f
- trophectoderm (TE) cells, 11, 13–14, 107–9, 135, 143, 149
- trophoblast cells, 24, 160
- ultramicrofluorescence (UMF), 128–30
- ultrastructures of refractile bodies, 74
- unusual sperm/semen samples, 65–6
- useable blastocyst rates, 56–8
- uterine natural killer cells (uNK), 23
- uterine tract microenvironment, 24
- uterodomes, 22
- uteroplacental blood flow, 23
- vacuoles, 73–4, 74f, 75
- vitamin E supplementation, 16
- volatile organic compounds (VOCs), 63
- whole genome amplification (WGA), 138–47, 161
- zona pellucida (ZP)
 - acidified Tyrode's solution, 151
 - blastocentesis technique, 160–1, 161f
 - blastocyst fluid and, 160
 - fully hatched blastocyst, 154–5
 - introduction to, 70
 - laser-assisted opening, 151
 - mechanical ZP opening, 151
 - opening procedure, 151
 - overview of, 72
 - partial-zona-dissection (PZD) microneedle, 151
 - poor-quality blastocyst, 154–5
 - thinning of, 107
 - trophectoderm (TE) biopsy, 152–3, 154f
 - zona breakers, 90
- zygote stage
 - cytoplasmic halo, 101–3, 102f
 - pronuclear pattern, 100–1, 102f
 - scoring of, 103
 - static evaluations for morphological assessment, 100–3